Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 9;20(1):255.
doi: 10.1186/s12957-022-02715-x.

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Yifeng Mao  1   2 , Mingqiu Hu  3   4   5 , Gaowei Yang  6 , Erke Gao  6 , Wangwang Xu  6
Affiliations
Meta-Analysis

Cytoreductive prostatectomy improves survival outcomes in patients with oligometastases: a systematic meta-analysis

Yifeng Mao et al. World J Surg Oncol. .

Abstract

Background: Whether cytoreductive prostatectomy (CRP) should be performed in patients with oligometastatic prostate cancer (OPC) remains controversial. The goal of this systematic meta-analysis was to assess the efficacy of CRP as a treatment for OPC.

Methods: This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. Data sources included publications in the PubMed, Embase, the Cochrane Library, EBSCO, and Web of Science (SCI) databases as of May 2022. Eligible articles included prospective studies comparing the efficacy of CRP to a lack of CRP in patients with OPC.

Results: In total, 10 publications incorporating 888 patients were analyzed. Tumor-reducing prostatectomy was found to have no significant effect on long-term or short-term OS [OR = 2.26, 95% CI (0.97, 5.28), P = 0.06] and [OR = 1.73, 95% CI (0.83, 3.58), P = 0.14], but it significantly improved patient long-term or short-term CSS [OR = 1.77, 95% CI (1.01, 310), P = 0.04] and [OR = 2.71, 95% CI (1.72, 4.29), P < 0.0001] and PFS [OR = 1.93, 95% CI (1.25, 2.97), P = 0.003].

Conclusion: These results suggest that cytoreductive prostatectomy can confer survival benefits to OPC patients.

Trial registration: INPLASY protocol 202260017 https://doi.org/10.37766/inplasy2022.6.0017 .

Keywords: Cancer-specific survival; Cytoreductive prostatectomy; Oligometastases; Overall survival; Progression-free survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Search strategy flow diagram
Fig. 2
Fig. 2
Forest plot corresponding to patient overall survival at 3 years (A) and 5 years (B) in the cytoreductive prostatectomy group and the androgen deprivation therapy group. No significant difference in OS was observed at 3 years (A) [OR = 1.73, 95% CI (0.83, 3.58), P = 0.14 > 0.05] or 5 years (B) [OR = 2.26, 95% CI (0.97, 5.28), P = 0.06 > 0.05]
Fig. 3
Fig. 3
Forest plot corresponding to patient CSS at 3 years (A) and 5 years (B) in the cytoreductive prostatectomy group and the androgen deprivation therapy group. Patients in the group that underwent surgery exhibited significantly higher CSS at 3 years (A) [OR = 1.77, 95% CI (1.01, 3.10), P = 0.04 < 0.05] but not at 5 years (B) [OR = 2.71, 95% CI (0.98, 4.63), P = 0.06 > 0.05]
Fig. 4
Fig. 4
Forest plot corresponding to patient PFS at 5 years in the cytoreductive prostatectomy group and the androgen deprivation therapy group. A significant difference in 5-year PFS was observed between the surgery and non-surgery groups, with survival being significantly longer for patients that underwent surgery [OR = 1.93, 95% CI (1.25, 2.97), P = 0.003 < 0.05]
See this image and copyright information in PMC

References

    1. Crocetto F, Buonerba C, Caputo V, Ferro M, Persico F, Trama F, Iliano E, Rapisarda S, Bada M, Facchini G, Verde A, Placido S, Barone B. Urologic malignancies: advances in the analysis and interpretation of clinical findings. Future Sci OA. 2021;7(4):FSO674. doi: 10.2144/fsoa-2020-0210. - DOI - PMC - PubMed
    1. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10(2):63–89. doi: 10.14740/wjon1191. - DOI - PMC - PubMed
    1. Crocetto F, Barone B, Caputo VF, Fontana M, de Cobelli O, Ferro M. BRCA germline mutations in prostate cancer: the future is tailored. Diagnostics (Basel). 2021;11(5):908. doi: 10.3390/diagnostics11050908. - DOI - PMC - PubMed
    1. Kaur H, Salles DC, Murali S, et al. Genomic and clinicopathologic characterization of ATM-deficient prostate cancer. Clin Cancer Res. 2020;26(18):4869–4881. doi: 10.1158/1078-0432.CCR-20-0764. - DOI - PMC - PubMed
    1. Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: Esmo clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119–1134. doi: 10.1016/j.annonc.2020.06.011. - DOI - PubMed